D. van der Heijde

LONG-TERM RADIOGRAPHIC OUTCOME IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH GOLIMUMAB : 104 WEEK RESULTS FROM THE GO-REVEAL STUDY

D. Gladman, P. Mease, A. Kavanaugh, 2012 .

Abatacept in the Treatment of Active Psoriatic Arthritis : 24-Week Results from a Phase III Study

A. Gottlieb, D. Gladman, P. Mease, 2017 .

EFFECT OF CERTOLIZUMAB PEGOL ON SIGNS AND SYMPTOMS IN PATIENTS WITH PSORIATIC ARTHRITIS WITH OR WITHOUT PRIOR ANTI-TNF EXPOSURE : 24-WEEK RESULTS OF A PHASE III DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED STUDY

P. Mease, R. Fleischmann, D. Kielar, 2012 .

Predictors of ASDAS Major Improvement in Patients with Ankylosing Spondylitis Receiving Their First TNF Inhibitor. Results From a Longitudinal Observational Study

T. Kvien, E. Rødevand, K. Mikkelsen, 2011 .

Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis : 24-Week Efficacy and Safety Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study Using Subcutaneous Dosing.

P. Rahman, P. Conaghan, P. Mease, 2014 .

Long-Term Safety and Efficacy of Certolizumab Pegol over 96 Weeks in Patients with Psoriatic Arthritis with and without Prior Tumor Necrosis Factor Inhibitor Exposure.

D. Gladman, A. Deodhar, P. Mease, 2014 .